Case Reports
doi: 10.1097/01.inf.0000134314.65398.bf.
Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children
Affiliations
- PMID: 15295229
- DOI: 10.1097/01.inf.0000134314.65398.bf
Item in Clipboard
Case Reports
Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children
Pediatr Infect Dis J.
2004 Aug.
Abstract
A human immunodeficiency virus-infected boy with Scedosporium apiospermum otomastoiditis and a girl with diabetes mellitus and Mucor sinusitis and orbital cellulitis had life-threatening disease progression despite antifungal treatment. Interferon-gamma and granulocyte-macrophage or granulocyte colony-stimulating factor were added, with good functional outcome in both children. Adjunctive therapy with interferon-gamma, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor can be considered for refractory invasive fungal infections.
Similar articles
-
Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia.Cancer. 2005 Jul 1;104(1):199-204. doi: 10.1002/cncr.21142. Cancer. 2005. PMID: 15929126
-
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.Diagn Microbiol Infect Dis. 2004 Dec;50(4):247-51. doi: 10.1016/j.diagmicrobio.2004.07.011. Diagn Microbiol Infect Dis. 2004. PMID: 15582297
-
Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.Antimicrob Agents Chemother. 2004 Oct;48(10):3801-5. doi: 10.1128/AAC.48.10.3801-3805.2004. Antimicrob Agents Chemother. 2004. PMID: 15388437 Free PMC article.
-
Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma.J Infect Dis. 2002 May 15;185(10):1490-501. doi: 10.1086/340221. Epub 2002 Apr 19. J Infect Dis. 2002. PMID: 11992286 Review.
-
Use of recombinant interferons and hematopoietic growth factors in patients infected with human immunodeficiency virus.Rev Infect Dis. 1991 Sep-Oct;13(5):979-84. doi: 10.1093/clinids/13.5.979. Rev Infect Dis. 1991. PMID: 1720567 Review.
Cited by
-
Lethargy and vision loss: successful management of rhinocerebral mucormycosis.BMJ Case Rep. 2016 Jun 2;2016:bcr2016215855. doi: 10.1136/bcr-2016-215855. BMJ Case Rep. 2016. PMID: 27256997 Free PMC article.
-
Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.J Clin Med. 2022 Jun 23;11(13):3620. doi: 10.3390/jcm11133620. J Clin Med. 2022. PMID: 35806905 Free PMC article. Review.
-
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Clin Microbiol Rev. 2005 Jul;18(3):556-69. doi: 10.1128/CMR.18.3.556-569.2005. Clin Microbiol Rev. 2005. PMID: 16020690 Free PMC article. Review.
-
Recurrent Scedosporium apiospermum Cutaneous Infection in a Patient with Rheumatoid Arthritis: The Potent Role of IL-6 Signaling Pathway Blockade: A Case-Based Review.J Fungi (Basel). 2023 Jun 18;9(6):683. doi: 10.3390/jof9060683. J Fungi (Basel). 2023. PMID: 37367619 Free PMC article. Review.
-
Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.Antimicrob Agents Chemother. 2009 Aug;53(8):3569-71. doi: 10.1128/AAC.00456-09. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451289 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
